Homepage > Company > Media > Pharma News > 2021 > General Atlantic-backed Centessa targets $1.7 bln valuation in U.S. IPO

General Atlantic-backed Centessa targets $1.7 bln valuation in U.S. IPO

Centessa Pharmaceuticals said on Monday it was aiming for a valuation of up to $1.7 billion in its initial public offering, as reported Sharenet on Monday.

The drugmaker is offering 15 million shares at a price between $18 and $20.

At the top end of this range, the company would raise $300 million.

May 24th, 2021

https://www.firstwordpharma.com/

Read also

Granules India's Hyderabad-based facility gets first U.S. FDA approval

Granules India said that its subsidiary Granules Life Sciences (GLS), located in Hyderabad, has received U.S. Food and Drug Administration (FDA) approval for a product that was the sub...

Verismo Therapeutics Presents

Verismo Therapeutics Presents Promising Preclinical Data at SITC 2025 for SynKIR™-110 in Solid Tumors

FDA Commissioner on lifting warnings on hormone therapy for menopause

The Food and Drug Administration says it is removing the black box safety warnings from all hormone therapy creams, pills and other treatments prescribed to ease the symptoms of menopause and perimeno...

FDA grants fast track designation to drug combo for colorectal cancer

The U.S. Food and Drug Administration has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer, following encouraging results from a clinical trial led in part by ...